Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, March 31, 2023.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2023 (2023-03-31): -330.92%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-179.08%
RETURN ON EQUITY (ROE) AVG 3Y
-124.26%
RETURN ON EQUITY (ROE) AVG 5Y
-335.67%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Atara Biotherapeutics, Inc.
Market Cap
$87.85M
Return on Equity (ROE)
N/A
TTM Avg
-179.08%
3Y Avg
-124.26%
5Y Avg
-335.67%
Market Cap
$87.96M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$87.27M
Return on Equity (ROE)
-477.87%
TTM Avg
-156.51%
3Y Avg
-83.51%
5Y Avg
-25.98%
Market Cap
$89.44M
Return on Equity (ROE)
N/A
TTM Avg
329.82%
3Y Avg
69.21%
5Y Avg
21.28%
Market Cap
$89.78M
Return on Equity (ROE)
-32.15%
TTM Avg
-60.32%
3Y Avg
-93.79%
5Y Avg
-79.41%
Market Cap
$85.86M
Return on Equity (ROE)
-105.20%
TTM Avg
-53.79%
3Y Avg
-41.98%
5Y Avg
-32.71%
Market Cap
$90.20M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
Market Cap
$90.37M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$90.64M
Return on Equity (ROE)
48.20%
TTM Avg
-54.60%
3Y Avg
-54.70%
5Y Avg
-44.17%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | $87.85M | N/A | -179.08% | -124.26% | -335.67% |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 45.93% | 16.96% | -19.36% | -13.87% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | -477.87% | -156.51% | -83.51% | -25.98% |
| electroCore, Inc. (ECOR)vs › | $89.44M | N/A | 329.82% | 69.21% | 21.28% |
| Equillium, Inc. (EQ)vs › | $89.78M | -32.15% | -60.32% | -93.79% | -79.41% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | -105.20% | -53.79% | -41.98% | -32.71% |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 2.51% | -5.84% | -10.75% | -7.81% |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | -268.09% | -238.76% | -155.55% | -124.74% |
| Rallybio Corporation (RLYB)vs › | $90.64M | 48.20% | -54.60% | -54.70% | -44.17% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | -50.80% | -124.86% | -88.30% | -60.21% |
ROE
N/A
ROA
-79.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2023-03-31 | -330.92% |
| 2022-12-31 | -180.28% |
| 2022-09-30 | -132.05% |
| 2022-06-30 | -96.18% |
| 2022-03-31 | -155.99% |
| 2021-12-31 | -121.65% |
| 2021-09-30 | -105.79% |
| 2021-06-30 | -95.85% |
| 2021-03-31 | -78.05% |
| 2020-12-31 | -66.32% |
| 2020-09-30 | -85.84% |
| 2020-06-30 | -248.85% |
| 2020-03-31 | -638.49% |
| 2019-12-31 | -757.72% |
| 2019-09-30 | -918.51% |
| 2019-03-31 | -899.90% |
| 2018-12-31 | -680.82% |
| 2018-09-30 | -461.48% |
| 2018-06-30 | -350.80% |
| 2018-03-31 | -308.03% |
| 2017-12-31 | -671.81% |
| 2017-09-30 | -497.26% |
| 2017-06-30 | -437.23% |
| 2017-03-31 | -378.07% |
| 2016-12-31 | -311.54% |
| 2016-09-30 | -303.71% |
| 2016-06-30 | -236.20% |
| 2016-03-31 | -212.69% |
| 2015-12-31 | -181.60% |
| 2015-09-30 | -139.33% |
| 2015-06-30 | -271.69% |
| 2015-03-31 | -181.33% |
| 2014-12-31 | -271.42% |
| 2014-06-30 | -313.96% |
